Blog
RSS FeedPosted by Michael Wonder on 11 Feb 2025
Nivolumab and ipilimumab for the first-line treatment of patients with metastatic colorectal cancer with high microsatellite instability or mismatch repair deficiency
10 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 05 Feb 2025
Pembrolizumab for adjuvant treatment of patients with resected non-small-cell lung cancer (final guidance)
5 February 2025 - NICE has published final evidence-based recommendations on the use of pembrolizumab (Keytruda) for the adjuvant treatment ...
Posted by Michael Wonder on 05 Feb 2025
Elacestrant dihydrochloride for the treatment of patients with advanced, oestrogen receptor positive, HER2 negative breast cancer with an ESR1 mutation after endocrine treatment (final guidance)
5 February 2025 - Evidence-based recommendations on elacestrant (Korserdu) for treating oestrogen receptor-positive HER2-negative advanced breast cancer with an ESR1 mutation ...
Posted by Michael Wonder on 04 Feb 2025
Durvalumab with tremelimumab for the first-line treatment of patients with advanced or unresectable hepatocellular carcinoma
4 February 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 31 Jan 2025
Thousands of people with a severe dust mite allergy are set to benefit from life-changing treatment
30 January 2025 - We've recommended an innovative daily tablet treatment shown to reduce symptoms and improve quality of life. ...
Posted by Michael Wonder on 28 Jan 2025
Spesolimab for the treatment of patients with generalised pustular psoriasis flares
24 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 28 Jan 2025
Harnessing expertise to improve patient access to innovative health technologies
28 January 2025 - Introducing the Medicines and Medical Devices Access Initiative: a new collaboration that aims to improve patient access ...
Posted by Michael Wonder on 28 Jan 2025
Tarlatamab for previously treated patients with advanced small-cell lung cancer
28 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 23 Jan 2025
Vadadustat for the treatment of adults with symptomatic anaemia on dialysis for chronic kidney disease
23 January 2025 - NICE has published final evidence-based recommendations on the use of vadadustat (Vafseo) for the treatment of ...
Posted by Michael Wonder on 22 Jan 2025
Abiraterone acetate with niraparib tosylate monohydrate and prednisone for untreated hormone-relapsed metastatic prostate cancer
22 January 2025 - NICE is unable to make a recommendation on the use in the NHS of abiraterone acetate with ...
Posted by Michael Wonder on 21 Jan 2025
NICE has made six times more lung cancer treatment recommendations over the past ten years than in the previous decade
21 January 2025 - We have also recommended osimertinib for routine use on the NHS today. ...
Posted by Michael Wonder on 17 Jan 2025
International collaboration provides new guidance on the use of surrogate outcomes in cost effectiveness analysis
17 January 2025 - Recommendations will help organisations that evaluate new drugs establish whether their use will result in longer-term benefits ...
Posted by Michael Wonder on 15 Jan 2025
Capivasertib in combination with fulvestrant for the treatment of patients with advanced, hormone receptor positive, HER2 negative breast cancer after endocrine treatment
14 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...
Posted by Michael Wonder on 14 Jan 2025
Design and features of pricing and payment schemes for health technologies: a scoping review and a proposal for a flexible need driven classification
13 January 2025 - In a context of growing clinical and financial uncertainty, pricing and payment schemes can act as possible ...
Posted by Michael Wonder on 13 Jan 2025
Marstacimab for the treatment of patients 12 years of age and older with severe haemophilia A or severe haemophilia B
13 January 2025 - The Department of Health and Social Care has asked NICE to produce guidance on the use ...